[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PA8846201A1 - Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales - Google Patents

Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales

Info

Publication number
PA8846201A1
PA8846201A1 PA20098846201A PA8846201A PA8846201A1 PA 8846201 A1 PA8846201 A1 PA 8846201A1 PA 20098846201 A PA20098846201 A PA 20098846201A PA 8846201 A PA8846201 A PA 8846201A PA 8846201 A1 PA8846201 A1 PA 8846201A1
Authority
PA
Panama
Prior art keywords
anilina
sulfoximine
derivatives
production
same
Prior art date
Application number
PA20098846201A
Other languages
English (en)
Inventor
Jaulelat Rolf
Schulze Julia
Luecking Ulrich
Siemeister Gerhard
Lienau Philip
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PA8846201A1 publication Critical patent/PA8846201A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

DERIVADOS DE ANILINA-PIRIMIDINA SUSTITUIDOS CON SULFOXIMINA DE LA FÓRMULA(I)MÉTODOS DE PRODUCCIÓN DE LOS MISMOS Y SU USO COMO MEDICACIÓN PARA EL TRATAMIENTO DE DIVERSAS ENFERMEDADES.
PA20098846201A 2008-10-21 2009-10-19 Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales PA8846201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08167113A EP2179991A1 (de) 2008-10-21 2008-10-21 Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
PA8846201A1 true PA8846201A1 (es) 2010-05-26

Family

ID=40282208

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20098846201A PA8846201A1 (es) 2008-10-21 2009-10-19 Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales

Country Status (38)

Country Link
US (1) US8735412B2 (es)
EP (2) EP2179991A1 (es)
JP (1) JP5564054B2 (es)
KR (1) KR20110069115A (es)
CN (1) CN102197029B (es)
AR (1) AR074053A1 (es)
AU (1) AU2009306733C1 (es)
BR (1) BRPI0920112A2 (es)
CA (1) CA2739739C (es)
CO (1) CO6361926A2 (es)
CR (1) CR20110210A (es)
CU (1) CU24052B1 (es)
CY (1) CY1115590T1 (es)
DK (1) DK2350026T3 (es)
DO (1) DOP2011000107A (es)
EA (1) EA019230B1 (es)
EC (1) ECSP11010992A (es)
ES (1) ES2499028T3 (es)
HN (1) HN2011001019A (es)
HR (1) HRP20140830T1 (es)
IL (1) IL211713A (es)
MA (1) MA32723B1 (es)
MX (1) MX2011004238A (es)
MY (1) MY155230A (es)
NZ (1) NZ592314A (es)
PA (1) PA8846201A1 (es)
PE (1) PE20110546A1 (es)
PL (1) PL2350026T3 (es)
PT (1) PT2350026E (es)
RS (1) RS53523B1 (es)
SA (1) SA109300632B1 (es)
SI (1) SI2350026T1 (es)
TN (1) TN2011000199A1 (es)
TW (2) TWI496774B (es)
UA (1) UA103500C2 (es)
UY (1) UY32190A (es)
WO (1) WO2010046035A1 (es)
ZA (1) ZA201103727B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2464633A1 (en) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
DE102010014426A1 (de) 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
DE102010014427A1 (de) 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Kombinationen neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
DE102010046720A1 (de) * 2010-09-23 2012-03-29 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von pan-CDK-Inhibitoren der Formel (l), sowie Intermediate der Herstellung
TWI555737B (zh) * 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
DE102011080992A1 (de) * 2011-08-16 2013-02-21 Bayer Pharma AG Verwendung von MAD2L2 als Stratifikationsmarker bei der Behandlung von Brusttumoren mit neuen pan-CDK-Inhibitoren
DE102011080991A1 (de) * 2011-08-16 2013-02-21 Bayer Pharma AG Verwendung von CCNE2 als Stratifikationsmarker bei der Behandlung von Brusttumoren mit neuen pan-CDK-Inhibitoren
JP5976814B2 (ja) 2011-09-16 2016-08-24 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ スルホキシイミン基を含有する二置換５−フルオロピリミジン誘導体
AU2013234451A1 (en) * 2012-03-21 2014-09-25 Bayer Intellectual Property Gmbh Use of (RS)-S-cyclopropyl-S-(4-{[4-{[1R, 2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl] amino}phenyl)sulfoximide for treating specific tumours
CA2964696C (en) * 2014-10-16 2022-09-06 Bayer Pharma Aktiengesellschaft Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group
CA3111977A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4029650A1 (de) 1990-09-19 1992-03-26 Hoechst Ag 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
DE69832715T2 (de) 1997-07-12 2007-01-11 Cancer Research Technology Ltd. Cyclin-abhängige-kinase inhibierende purinderivate
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
WO2000012486A1 (en) 1998-08-29 2000-03-09 Astrazeneca Ab Pyrimidine compounds
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
IL159120A0 (en) 2001-05-29 2004-05-12 Schering Ag Cdk inhibiting pyrimidines, production thereof and their use as medicaments
AU2003212282A1 (en) 2002-03-11 2003-09-22 Schering Aktiengesellschaft Cdk inhibiting 2-heteroaryl pyrimidine, the production thereof, and use thereof as a medicament
US7504410B2 (en) 2002-11-28 2009-03-17 Schering Aktiengesellschaft Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
DE10349423A1 (de) * 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
WO2006034872A1 (de) * 2004-09-29 2006-04-06 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-anilinopyrimidine als zellzyklus -kinase oder rezeptortyrosin-kinase inhibitoren, deren herstellung und verwendung als arzneimittel
DE102005062742A1 (de) * 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
DE102006027156A1 (de) 2006-06-08 2007-12-13 Bayer Schering Pharma Ag Sulfimide als Proteinkinaseinhibitoren
EP2179992A1 (de) * 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
JP5564054B2 (ja) 2014-07-30
AU2009306733B2 (en) 2015-11-12
TWI458716B (zh) 2014-11-01
CA2739739C (en) 2016-12-20
TWI496774B (zh) 2015-08-21
MY155230A (en) 2015-09-30
IL211713A0 (en) 2011-06-30
JP2012506391A (ja) 2012-03-15
ZA201103727B (en) 2014-11-26
US20110294838A1 (en) 2011-12-01
EA201100623A1 (ru) 2011-12-30
PL2350026T3 (pl) 2014-11-28
MA32723B1 (fr) 2011-10-02
CU24052B1 (es) 2014-12-26
PE20110546A1 (es) 2011-08-12
UY32190A (es) 2010-05-31
TW201444803A (zh) 2014-12-01
SI2350026T1 (sl) 2014-10-30
TW201020237A (en) 2010-06-01
NZ592314A (en) 2013-02-22
IL211713A (en) 2015-04-30
ES2499028T3 (es) 2014-09-26
AU2009306733C1 (en) 2016-07-14
EP2350026A1 (de) 2011-08-03
BRPI0920112A2 (pt) 2015-12-22
CO6361926A2 (es) 2012-01-20
DK2350026T3 (da) 2014-09-15
SA109300632B1 (ar) 2013-07-04
US8735412B2 (en) 2014-05-27
DOP2011000107A (es) 2011-05-15
MX2011004238A (es) 2011-05-23
PT2350026E (pt) 2014-09-12
EP2179991A1 (de) 2010-04-28
CN102197029A (zh) 2011-09-21
RS53523B1 (en) 2015-02-27
CU20110088A7 (es) 2011-12-28
AR074053A1 (es) 2010-12-22
CN102197029B (zh) 2014-05-14
UA103500C2 (uk) 2013-10-25
CY1115590T1 (el) 2017-01-04
KR20110069115A (ko) 2011-06-22
HRP20140830T1 (hr) 2014-11-21
AU2009306733A1 (en) 2010-04-29
HN2011001019A (es) 2013-07-01
CA2739739A1 (en) 2010-04-29
TN2011000199A1 (en) 2012-12-17
EP2350026B1 (de) 2014-06-18
EA019230B1 (ru) 2014-02-28
CR20110210A (es) 2011-06-08
ECSP11010992A (es) 2011-05-31
WO2010046035A1 (de) 2010-04-29

Similar Documents

Publication Publication Date Title
PA8846201A1 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CY1116424T1 (el) Παραγωγο αδενινης ως αναστολεας ρι3κ
DOP2010000013A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
NI201000004A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
UY31277A1 (es) Nuevos derivados de 6-triazolopiridacina -sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmacéuticas y nueva utilizacion principalmente como inhibidores de met
CO6290656A2 (es) Derivados heterociclicos de urea y metodos de uso de los mismos -211
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
CO6362015A2 (es) Derivados de acido 1-amino-2ciclobutiletilboronico
ECSP12011720A (es) Compuestos heterocíclicos y usos de los mismos
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
UY32259A (es) Nuevos compuestos de hidroxiareno, preparados farmaceuticos que los contienen y aplicaciones
ECSP14026138A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
UY32848A (es) Compuestos heterocíclicos de oxima
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
AR079945A1 (es) Derivados de pirazina como inhibidores de glucogeno sintasa quinasa 3 (gsk3)
UY31864A (es) Derivados de urea hetericíclica y métodos de uso de los mismos-332
CR20160290A (es) Inhibidores tetracíclicos de autotaxina
UY32856A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
UY32694A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
CO6592046A2 (es) 5-alquinil pirimidas y su uso como inhibidores de quinasa
NI201200103A (es) NUEVOS DERIVADOS ( HETEROCICLO - TETRAHIDRO - PIRIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y ( HETEROCICLO - DIHIDRO - PIRROLIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y SU UTILIZACIÓN COMO INHIBIDORES DE p75